News | March 29, 2022
USFDA approves EUA for second booster dose of Moderna
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
